PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)

Subjects

Subjects :

Oncology
medicine.medical_specialty
business.industry
Health Policy
Public Health, Environmental and Occupational Health
medicine.disease
Temsirolimus
First line treatment
Interferon
Renal cell carcinoma
Internal medicine
medicine
In patient
business
Quality adjusted survival
medicine.drug

Details

ISSN :

10983015

Volume :

10

Issue :

6

Database :

OpenAIRE

Journal :

Value in Health

Accession number :

edsair.doi.dedup.....f4bbaa656475be51a6b39a594cf0a406

Full Text :

https://doi.org/10.1016/s1098-3015(10)65222-9